AI-driven microbiome Leverage Xbiome's AI and data platform to identify collaboration opportunities in AI-assisted drug discovery, biomarker development, and precision gut microbiome therapies for clients seeking faster development timelines and higher success rates.

Clinical-stage assets Target pharma and biotech partners interested in co-development or licensing of M201 and the AUP-16 four-in-one therapy, highlighting Xbiome's recent asset acquisition and readiness to advance into late-stage clinical milestones.

Global expansion Position Xbiome’s plans for United States Phase 1b trials and China-based initiatives as a pathway for international partnerships, contract research, and technology licensing to companies aiming to de-risk gut microbiome programs across regions.

Financial strength Highlight substantial Series B funding and a broad investor base to support joint ventures, sponsored research, and platform collaborations, offering potential financiers and partners confidence in scale-up capabilities.

Disease focus Align with potential customers targeting dysbiosis-related diseases by presenting Xbiome’s gut microbiome platform as a method to accelerate therapeutic candidates, companion diagnostics, and personalized treatment strategies.